Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir Against Coronavirus Disease 2019.

Hailey J ParkSophia T TanTomás M LeónSeema JainRobert SchechterNathan C Lo

Published in: Open forum infectious diseases (2023)

These findings suggest that prioritizing uptake of bivalent boosters and nirmatrelvir-ritonavir among older age groups (≥65 years) would be most effective (based on NNT) but would not address the entire burden of severe COVID-19.

Keyphrases

coronavirus disease
public health
antiretroviral therapy
respiratory syndrome coronavirus
early onset
sars cov
risk factors
global health
drug induced